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gender is attributable to the presence of concomitant clinical comor-
bidities. The adjusted effect of gender on outcomes was uniform be-
tween clinical presentations.
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BACKGROUND There is limited information of clinical outcomes after
chronic total occlusion (CTO) revascularization by drug-eluting stent
(DES) compared to coronary artery bypass grafting (CABG). We per-
formed the long-term (5-year) follow-up of patients who underwent
percutaneous coronary intervention (PCI) using DES or CABG for CTO
revascularization.
METHODS We identiﬁed 883 patients with CTO who underwent PCI
using DES (n¼484) or CABG (n¼399) in Asan Medical Center between
January 2005 and May 2010. The primary end point was a major
adverse cardiac event (MACE), which was composite of death from
any cause, myocardial infarction or target vessel revascularization.
RESULTS After adjustment for difference in baseline characteristics,
the 5-year incidence of MACE was similar between two groups (hazard
ratio [HR]:0.80; 95% conﬁdence interval [CI]: 0.51-1.27, p¼0.35). In
addition, individual component of the primary endpoint, including
death (HR: 0.67; 95% CI: 0.40-1.14, p¼0.14), myocardial infarction
(HR: 0.57; 95% CI: 0.11-2.99, p¼0.51), and target vessel revasculari-
zation (HR: 1.43; 95% CI: 0.47-4.37, p¼0.53) were not signiﬁcantly
different between two groups. However, the risk of new lesion
revascularization was signiﬁcantly higher (HR: 19.79; 95% CI: 2.04 –
192.37, p¼0.01) and risk of cerebrovascular event was lower (HR: 0.12;
95% CI: 0.02-0.7, p¼0.02) in the DES group.
Table 1. Adjusted Hazard Ratio for Clinical Outcomes at 5 Year After PCI using DES as Compared With After
CABG in the Overall PopulationClinical outcomes Adjusted HR (95% CI) P valueMACEy 0.80 (0.51 – 1.27) 0.35
Death 0.67 (0.40 – 1.14) 0.14Cardiac Death 0.56 (0.30 – 1.06) 0.08Myocardial Infarction 0.57 (0.11 – 2.99) 0.51Death or MI 0.70 (0.42 – 1.15) 0.16Repeat RevascularizationTarget Vessel Revascularization 1.43 (0.47 – 4.37) 0.53CTO Vessel Revascularization 3.41 (0.60 – 19.33) 0.17New Lesion Revascularization 19.79 (2.04 – 192.37) 0.01Cerebrovascular Event 0.12 (0.02 – 0.7) 0.02Major Bleeding 0.57 (0.22 – 1.48) 0.24yThe composite of death from any causes, myocardial infarction and target vessel revascularizationCONCLUSIONS For patients with CTO, DES treatment, compared with
CABG, showed similar rates of mortality and the combined end point
of MACE up to 5 years.
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BACKGROUND Dual antiplatelet therapy (DAPT) prevents myocardial
infarction (MI), yet increases bleeding complications after percuta-
neous coronary intervention (PCI). Whether or not the mortality risks
after each type of adverse event are comparable, both in magnitude
and over time, to one another is unclear.
METHODS We examined associations between MI, bleeding requiring
hospitalization (BRH) and one-year mortality in the PROMETHEUS
cohort, a multicenter observational study (n¼19,914) of acute coro-
nary syndrome (ACS) patients treated with PCI. Hazard ratios for MI
and BRH were generated using Cox regression with each adverse
event entered as a time-updated covariate.
RESULTS One-year rates of all-cause mortality, MI and BRH were
5.6% (n¼963), 5.5% (n¼977) and 4.4% (n¼776), respectively. Patients
with BRH were older, more often female with a higher frequency of
renal dysfunction compared to those with MI. In contrast, diabetes
mellitus, current smoking and prior PCI were more commonly
observed in those with MI. Adjusted HRs for mortality associated with
MI and BRH were 2.3 (95% CI 1.9-2.8) and 2.3 (95% CI 1.8-2.8),
respectively. Mortality risk was highest up to 30 days after either
event, and remained signiﬁcantly increased, albeit attenuated,
beyond 30 days post event (Figure).
